US 12,043,847 B2
Compositions and methods for treating acne
Robert L. Modlin, Sherman Oaks, CA (US); Jeffery F. Miller, Santa Monica, CA (US); Laura J. Marinelli, Los Angeles, CA (US); and Graham F. Hatfull, Pittsburgh, PA (US)
Assigned to The Regents of the University of California, Oakland, CA (US); and University of Pittsburgh—Of The Commonwealth System of Higher Education, Pittsburgh, PA (US)
Appl. No. 16/301,984
Filed by The Regents of the University of California, Oakland, CA (US); and University of Pittsburgh—Of The Commonwealth System of Higher Education, Pittsburgh, PA (US)
PCT Filed May 12, 2017, PCT No. PCT/US2017/032422
§ 371(c)(1), (2) Date Nov. 15, 2018,
PCT Pub. No. WO2017/200873, PCT Pub. Date Nov. 23, 2017.
Claims priority of provisional application 62/336,680, filed on May 15, 2016.
Prior Publication US 2019/0249149 A1, Aug. 15, 2019
Int. Cl. C12N 7/00 (2006.01); A61K 9/00 (2006.01); A61K 35/76 (2015.01); A61K 45/06 (2006.01); A61P 17/10 (2006.01); C12N 15/11 (2006.01)
CPC C12N 7/00 (2013.01) [A61K 9/0014 (2013.01); A61K 35/76 (2013.01); A61K 45/06 (2013.01); A61P 17/10 (2018.01); C12N 15/11 (2013.01); C12N 2310/20 (2017.05); C12N 2795/10321 (2013.01); C12N 2795/10332 (2013.01)] 10 Claims
 
1. A Propionibacterium acnes (P. acnes) bacteriophage mutant comprising a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) escape mutation, wherein the bacteriophage mutant is selected from the group consisting of P9.1-2A, P9.1-2B, P9.1-3, and P9.1-4.